The use of artemisinin in pregnant women, especially during the first trimester, is controversial due to potential risks to the developing fetus. Although studies suggest that artemisinin derivatives might have embryotoxic effects in animal models, the data in humans are less clear. The World Health Organization (WHO) recommends artemisinin-based combination therapies (ACTs) in the second and third trimesters but advises caution during the first trimester unless no other treatment options are available.
